Medtech Ends 2025 At Strategic Crossroads As AI Matures, IPO Windows Reopen And M&A Re-Accelerates
CEOs Say 2025 Delivered Commercial Momentum And Investor Confidence – But Execution In 2026 Will Depend On Regulatory Stability, Reimbursement Acceleration And Clinically Anchored AI.
The CEOs expect 2026 to test whether artificial intelligence remains “grounded in rigorous clinical science and patient safety rather than hype” and whether an unsettled regulatory and financing ecosystem stabilizes enough for large-scale execution. Picture Courtesy: Shutterstock
